Paint it purple: Ousted e-scooter company returns to Brisbane in merger
Neuron Mobility announced on Monday it had merged its Australian operations with Beam, and expected to return 700 purple – albeit rebranded and refurbished – e-scooters to Brisbane streets.
'After years of competing head to head, we're delighted to bring together the strengths of both companies under the Neuron banner,' Neuron Australia and New Zealand general manager Jayden Bryant said.
The former Beam vehicles are refitted with Neuron proprietary technology and safety features, sport orange branding and accents, and are bookable through the Neuron app.
Beam had previously been selling its old fleet to private e-mobility riders, after it was ousted last year after the company allegedly defrauded the Brisbane City Council with hundreds of 'ghost' machines.
Loading
The council revealed at the time a months-long investigation had shown the micromobility company exceeding its vehicle cap of 1800 vehicles by about 500 per day.
It claimed the company misreported its number of active e-scooters and e-bikes more than 250,000 times in the year leading up to July 22, 2024, amounting to a shortfall in fees to the council of more than $330,000. Beam scooters were then replaced by Neuron.
Brisbane has fluctuated between the two Singaporean micromobility companies and San Francisco-based Lime since 2019, when it first brought e-scooters onto Brisbane streets.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Sydney Morning Herald
12 minutes ago
- Sydney Morning Herald
Strategic CEO hire to drive NeuroScientific stem cell therapy release
NeuroScientific Biopharmaceuticals has made a second heavy-hitting appointment in less than a week, bringing in experienced Melbourne-based executive Nathan Smith as its chief executive officer, as the company gears up for the commercial release of its innovative StemSmart stem cell technology. Smith has extensive experience in cell and gene therapies in senior commercial, operational and strategic roles in Australia and the United States, which should prove invaluable as the company navigates the regulatory and commercial pathways for its innovative StemSmart technology. The company says his deep expertise in good practice manufacturing will be critical for converting the biotechnology startup into a scaled-up commercial stem cell company. NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopgen. StemSmart uses a specific type of stem cell, mesenchymal stromal stem cells (MSC), as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'I was attracted to NSB given the historical success of StemSmart in multiple serious clinical disorders and the clear potential of the technology for further development.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith Adding to the company's ranks of highly credentialled personnel, NeuroScientific announced on Friday that it had also recruited well-regarded Perth-based paediatric haematologist and oncologist Dr Catherine Cole as its chief medical officer. The news of both appointments has continued to fuel a stellar rise in the company's share price, which traded 11.3 per cent higher today to 24.5 cents on the best turnover since April. The company's share price is up 360 per cent since the start of June. Smith was the director of business development at Melbourne's Cell Therapies, which develops and manufactures advanced cell-based therapies and is located within the city's pioneering Peter MacCallum Cancer Centre. He has held key roles at Genzyme Corporation, Mesoblast Inc and GlaxoSmithKline in the US, as well as other leading companies in the cell therapy sector.

AU Financial Review
12 minutes ago
- AU Financial Review
‘We are not Luddites': AFR readers react to AI productivity boost
Almost 75 per cent of readers polled by The Australian Financial Review support a push by the Productivity Commission and business to embrace artificial intelligence as a way to lift productivity and boost the economy, but almost half do not support union involvement in AI regulation. Productivity Commission chairwoman Danielle Wood is recommending the Albanese government overhaul company tax, speed up planning approvals for infrastructure projects and embrace artificial intelligence to lift the economy out of stagnation. She said Australian full-time workers would be at least $14,000 better off by 2035 if productivity growth was boosted.

AU Financial Review
12 minutes ago
- AU Financial Review
Hedge fund LHC Capital profits from new bet in Dalrymple Bay
LHC Capital has made a 14 per cent return in the last three months buoyed by a strong rebound in some of the hedge fund's biggest stock bets and a timely investment in Queensland's Dalrymple Bay Infrastructure that it says is on the cusp of a re-rating. The Sydney-based short seller started buying shares in Dalrymple Bay, the world's largest metallurgical coal export terminal, after US private equity giant Brookfield Infrastructure sold down a large chunk of its stake last month.